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OVERVIEW — This paper provides a brief summary of the Medicaid prescrip-
tion drug benefit. It explains the mechanisms being used by states to control
their prescription drug spending within the Medicaid program. The paper also
highlights some of the concerns that have been expressed with these mecha-
nisms and the litigation that has been initiated in several states as a result of
these efforts. It takes a closer look at three states with cost-containment strat-
egies that have been the focus of increased scrutiny.
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As state lawmakers try to meet the competing needs of their constitu-
ents in a time of ever-decreasing revenues, Medicaid prescription drug
coverage has become a principal focus of states’ cost-containment ef-
forts. According to recent figures, states are facing deficits in the range
of $70 billion to $85 billion for state fiscal year (FY) 2004.1 In addition,
more than two-thirds of the states report shortfalls in their 2003 bud-
gets that together total at least $17.5 billion.2 Medicaid, which accounts
for 15 percent to 20 percent of state spending (second only to educa-
tion), has been a major contributor to these woes. Between 1997 and
2000, total Medicaid spending grew by 7.7 percent a year. And Medic-
aid drug expenditures grew more than twice as fast, rising by an aver-
age annual rate of 18.1 percent and accounting for nearly 20 percent of
the increase in Medicaid spending for this period.3
To address Medicaid’s impact on their budgetary crises, 44 states are
considering freezing or reducing Medicaid eligibility, benefits, and re-
imbursement rates during the 2003 legislative session.4 Thirty-nine states
anticipate changes in their Medicaid prescription drug programs.5 In
2002 alone, 210 bills on prescription drugs were considered in 39 states;
31 were passed.
States are implementing a wide range of policies to rein in prescription
drug costs or are expanding those already in place. These actions have
resulted in serious debate among the affected stakeholders: drug manu-
facturers, wholesalers, prescribers, pharmacies, and beneficiaries. Drug
manufacturers and pharmacies have expressed concern about adequate
reimbursement; prescribers worry about interference in their relation-
ship with patients; and beneficiaries and their advocates worry about
the affordability of and access to prescription drugs for low-income pa-
tients. These concerns are greatest in those states where multiple—in
many cases, up to four or five—cost-cutting measures are being imple-
mented simultaneously.
Increasing the tension and confusion around this issue has been the on-
going litigation that several states have faced as their efforts have been
challenged in the courts. One such case has already reached the U.S. Su-
preme Court and is being closely monitored by other states that have
their own draft legislation ready to be set in motion.
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MEDICAID PRESCRIPTION DRUG BENEFIT
Outpatient prescription drugs remain an optional benefit under federal
Medicaid law. However, all states currently provide prescription drug
coverage. As long as states opt to cover outpatient prescription drugs,
they must cover all drugs approved by the Food and Drug Administra-
tion (FDA) that have been produced by those manufacturers that have
entered into a rebate agreement with the secretary of the U.S. Depart-
ment of Health and Human Services (DHHS).6 In cases where states have
implemented a preferred drug list (PDL), federal Medicaid law allows
certain drugs to be excluded, but these drugs must be made available
through a prior authorization process (discussed in greater detail below).
The price that the state pays for outpatient prescription drugs includes
the amount the state pays the pharmacy for the drug itself and the fee the
state pays the pharmacist for dispensing the drug.7 Under the Medicaid
Drug Rebate Program, which was implemented as part of the Omnibus
Budget Reconciliation Act of 1990, the state receives a rebate from the
manufacturer for purchasing the drug.8 The act requires drug manufac-
turers to provide rebates to the states on a quarterly basis in exchange for
states’ reimbursement of their prescription drugs.9
Rebate amounts are established by federal statute and differ for brand-
name and generic drugs. For brand-name drugs, the rebate is (a) the greater
of 15.1 percent of the average manufacturer’s price (AMP) or the differ-
ence between the AMP and the manufacturer’s “best price”10 and (b) an
additional rebate for any product whose price increased by more than
the Consumer Price Index (CPI-U) since July 1, 1990.11 AMP is the average
price paid to manufacturers by wholesalers (after all discounts, includ-
ing manufacturer rebates) for a particular dosage form and strength of a
prescription drug distributed solely to the retail pharmacy class of trade.12
The AMP is not a published price. For generic drugs, the rebate is equal
to 11 percent of each product’s AMP.13
Beyond coverage of all drugs whose manufacturers have entered into a
federal rebate agreement, states are given significant flexibility in the de-
sign of their prescription drug benefit. Acceptable limitations on Medic-
aid drug coverage include the following:
■ A covered drug may be subject to prior authorization as long as the
system employed provides a response to a request within 24 hours and
enables the dispensing of a 72-hour supply of the prescription drug in
emergency situations.
■ States are permitted to exclude a prescription drug from coverage if
it falls into one of the following ten categories:
– Drugs used for anorexia, weight loss, or weight gain.
– Drugs used to promote fertility.
– Drugs used for cosmetic purposes or hair growth.
– Drugs used for the symptomatic relief of cough and colds.
States are given sig-
nificant flexibility in
the design of their pre-
scription drug benefit.
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– Drugs used for smoking cessation.
– Prescription vitamins and mineral products, except prenatal
vitamins and fluoride preparations.
– Nonprescription drugs.
– Drugs that a manufacturer ties to the sale of additional tests or
monitoring services purchased exclusively from the manufacturer
or its designee.
– Barbiturates (powerful depressants that slow down the central
nervous system).
– Benzodiazepines (medications that are frequently prescribed for
the symptomatic treatment of anxiety and sleep disorders).14
This restricted drug list is subject to periodic updates from the DHHS
secretary.
States may also establish formularies, provided they meet certain require-
ments. The formulary must be developed by a committee of physicians,
pharmacists, and other individuals appointed by the governor. The for-
mulary must include all drugs of any manufacturer that has entered into
a rebate agreement with the secretary. An otherwise covered drug may
be excluded from the formulary only if it does not have a “significant,
clinically meaningful therapeutic advantage in terms of safety, effective-
ness, or clinically meaningful outcome” over other formulary drugs, with
respect to the treatment of a given disease or condition. Drugs not con-
tained in the formulary must be available through an established prior
authorization process. States may also exclude drugs that are not being
used for a “medically accepted indication.”15
States also have the authority to impose other restrictions, with respect to
all drugs in a therapeutic class,16 including limitations on the quantity of
drugs per prescription or the number of refills per prescription. These
limitations must be necessary to “discourage waste, and may address
instances of fraud or abuse.”17
Cost Sharing
Under federal Medicaid law, states are permitted to impose copayments
on Medicaid beneficiaries for prescription drugs. Any copayment ap-
plied must be “nominal,” which has been defined as ranging from $0.50
to $3.00 per prescription, although waivers have been granted by the
Centers for Medicare and Medicaid Services (CMS) that permit
copayments as high as $5.00 per prescription. Certain individuals, such
as those under 18 years of age and pregnant women, as well as certain
categories of services, such as emergency services and family planning,
are exempt from copayments.18 Pharmacies providing drugs to Medic-
aid beneficiaries are prohibited from denying prescription drugs to any-
one who is unable to furnish a copayment.19
States may also estab-
lish formularies, pro-
vided they meet certain
requirements.
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STATE MECHANISMS FOR CONTROLLING
MEDICAID PRESCRIPTION DRUG SPENDING
The increasing budgetary pressure on states has led nearly all of them
to closely examine their Medicaid programs and develop ways to bring
costs under greater control. Of particular concern for states have been
growing expenditures for prescription drugs. Drug product costs ac-
count for over 90 percent of Medicaid prescription drug expenditures,
while pharmacist dispensing fees are less than 10 percent. The strategies
employed by states to control their prescription drug spending vary
greatly from state to state, but those that are most widely used can be
captured within some general categories. The increased financial re-
sponsibility or administrative burden of each of these controls is dis-
tinct and may fall on beneficiaries, providers, pharmacies, or drug manu-
facturers. While each of these approaches may affect multiple stake-
holders, they can be grouped into two general categories: (a) strategies
that place some limits on beneficiary access to prescription drugs or
increase the costs they incur and (b) strategies that reduce payments to
pharmacies and require additional rebates from drug manufacturers.
Strategies Directed at Beneficiary Drug Utilization
Prior Authorization — Prior authorization requires prescribers to ob-
tain approval before a prescription can be dispensed by a pharmacist to
a Medicaid patient. Some states permit both prescribers and pharmacies
to obtain prior authorization. This mechanism has been a part of state
Medicaid programs for many years and has been used to control the use
of costly drugs or those subject to abuse. Some argue that prior authori-
zation, which is generally linked to a state’s PDL, can serve as an impor-
tant mechanism for states to control the use of unnecessary or extremely
costly drugs. Between 35 and 40 states have some type of prior authori-
zation program,20 and it has been estimated that 27 of those states may
alter their prior authorization rules during the 2003 legislative session.21
As noted above, state prior authorization programs must comply with
the standards set forth in federal Medicaid law, which include a 24-hour
response time and the provision of a 72-hour supply of a drug in emer-
gency situations.22
Concern about access to needed drugs has led many states to develop
safeguards within their prior authorization programs. These safeguards
include “grandfather” provisions for beneficiaries taking a nonpreferred
drug, prior authorization based on age criteria, and maintenance of cov-
erage for certain classes of drugs without prior authorization. Examples
of these classes include certain mental health drugs, including
antipsychotics and antidepressants, and certain drugs used for the treat-
ment of HIV/AIDS.
Preferred Drug Lists/Formularies — Throughout the past few years,
PDLs, or formularies, have become an effective tool for states looking to
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control their prescription drug expenditures. A PDL is a list of drugs
approved by a state that can be dispensed without prior authorization.
As noted earlier, in order to comply with federal Medicaid law, such
lists must be established by a committee that is appointed by the state’s
governor and must include physicians and pharmacists; the list must
include all drugs of those manufacturers that have a rebate agreement
with the federal government, unless a drug does not have a “signifi-
cant, clinically meaningful therapeutic advantage over other formulary
drugs”23; and drugs excluded from a state’s list must be available through
a prior authorization process that meets certain requirements. In devel-
oping a PDL, the appointed committee reviews drugs by class (drugs
with similar clinical indications and/or chemical composition). Based on
each drug’s effectiveness, safety, clinical outcome data, and cost, several
from each class are selected for inclusion in the state’s PDL. The state
then negotiates for the lowest possible price for each drug on the list.
According to a survey conducted by the National Conference of State
Legislatures, 32 states are contemplating the creation of PDLs or alter-
ation of their existing PDLs during the 2003 legislative session.24 Given
the importance to manufacturers of having their drugs accessible with-
out prior approval, states have found that their PDLs can serve as lever-
age in securing supplemental rebates from manufacturers.
Increased Use of Generic Drugs — Whether through mandatory substi-
tution laws or through provider and pharmacy education and incentives,
many states are working to steer patients away from costly brand-name
drugs to less expensive generic alternatives. Given the potential savings
that generics can offer and the relatively modest impact on most benefi-
ciaries and providers, promoting their use has served as an important
and effective cost-saving measure. According to a 1998 Congressional
Budget Office report, generic drugs are approximately one-half the price
of brand-name drugs during their first year on the market.25 The actual
cost to a state Medicaid program, however, may vary depending on the
structure of its rebate program.
At least 15 states have opted to implement mandatory substitution that
requires pharmacists to dispense a generic drug for a brand-name drug,
when available.26 Almost all of these programs include processes that al-
low physicians to prescribe a brand-name drug for a patient. In some
states, physicians need only indicate their preference for the brand-name
drug on the prescription itself, while others require physicians to obtain
prior approval.
Some states have not gone as far as to require generic substitution but
have opted instead to use financial incentives and education. For ex-
ample, North Carolina recently promulgated a regulation that lowered
the dispensing fee paid to pharmacies for brand-name drugs from $5.60
to $4.00 but maintained the higher fee for generic drugs as an incentive
for pharmacies to dispense generics.27 Other states have implemented
A PDL is a list of drugs
approved by a state
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or are considering limits on the number of brand-name drugs that any
Medicaid patient may receive per month.28 Many states also have differ-
ing consumer copayments for brand-name and generic drugs. These
copayments, however, are so nominal that some argue that the differ-
ences may not lead to changes in consumer behavior. The federal prohibi-
tion against pharmacies’ denying a Medicaid beneficiary a prescription
drug if he or she is unable to furnish a copayment also constrains the
usefulness of this approach.
Federal Medicaid law sets a limit, the federal upper limit, on the pay-
ment amount the federal government will match for drugs with three or
more generic equivalents. The payment limit for these drugs is 150 per-
cent of the published price for the least costly therapeutic equivalent that
can be purchased by pharmacists (in quantities of 100 pills).29 States may
set their own payment ceilings for multiple source drugs—known as
maximum allowable cost (MAC) limits—provided they are lower than
the federal limits. In 2000, approximately 23 states set their own MAC
limits, according to the National Pharmaceutical Council. These limits
create an even greater incentive for pharmacists to dispense generics to
Medicaid beneficiaries, when available.
Increased Copayments/Limits on Prescription Drugs — In 2000, 28 of
44 state Medicaid programs imposed copayments on prescription
drugs.30 These copayments ranged from $0.50 to $3.00 per prescription,
the permissible limits within federal Medicaid law. Within these per-
missible limits, copayments were often higher for brand-name drugs.
States with CMS-approved waivers have copayments as high as $5.00
per prescription. As states continue to explore their options for reining
in prescription drug costs, many are turning to increased beneficiary
cost sharing. According to the Kaiser Commission on Medicaid and the
Uninsured, 19 states plan to establish or increase beneficiary copayments
for prescription drugs in FY 2003.31
One state’s effort in this area has been challenged by pharmacies in court.
In late 2002, the Oregon legislature instituted prescription drug
copayments for Medicaid beneficiaries not enrolled in managed care. Ef-
fective January 1, 2003, patients were required to pay $2.00 for generic
drugs and $3.00 for brand-name drugs. (Previously, Oregon had no
copayment.) This has generated concern among pharmacies, which will
ultimately absorb the cost of these increased copayments if Medicaid pa-
tients are unable to pay. Several pharmacies filed suit against the state in
January, alleging a violation of federal Medicaid law. According to the
Bureau of National Affairs, the complaint claims that the state implemented
the new rule without evaluating the impact of the reduced reimburse-
ment rate on pharmacies and Medicaid patients, as required by law.
In addition to increased copayments, states have used prescription drug
limits for beneficiaries as a means of controlling costs. A number of states
have had such limits in place for years. Others are now exploring them.
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At least 12 states are considering or have implemented policy changes
that will initiate or expand prescription drug limits. These include limits
on the number of prescriptions that Medicaid beneficiaries are entitled
to fill each month or each year, limits on the designated number of days
that constitutes a supply for each prescription, and caps on the number
of refills permitted.32 In some cases, generics and certain classes of drugs
are excluded from these limits. Several states have also instituted drug
management programs for beneficiaries who receive more than a cer-
tain number of prescriptions per month.
While relatively stringent drug limits have been a common practice in
many private-sector plans for years, consumer advocates are concerned
that limits on prescription drugs for the Medicaid population may lead
some beneficiaries to forgo necessary treatment because of cost. Others
worry that limiting access to needed prescription drugs may ultimately
lead to more costly treatments in the future.
Disease Management — More than 20 states are in the process of de-
veloping and implementing disease management programs for their Med-
icaid beneficiaries.33 With almost 80 percent of total Medicaid expendi-
tures attributable to the treatment of chronic conditions, including dia-
betes, asthma, and cardiovascular disease, states are looking to disease
management programs as a means of targeting and monitoring high-
risk individuals.34 State disease management programs can be structured
in a variety of ways. Some states outsource their programs to disease
management organizations; others develop their own internal systems;
others work with pharmaceutical companies; and some, like Florida,
combine more than one approach. Some observers have expressed con-
cern that disease management programs governed by pharmaceutical
companies may place too great an emphasis on the use of pharmaceuti-
cals rather than using a more comprehensive approach.
Missouri contracted with a health care technology company to develop
its disease management program. The program involves both pharma-
cists and physicians and focuses on asthma, depression, diabetes, and
heart failure. High-risk beneficiaries select a health care provider team
that includes a physician and a pharmacist. Through patient and pro-
vider education, as well as an innovative software system, the program
seeks to improve patient care and health outcomes and ensure the appro-
priate and efficient use of prescription drugs.
Pharmacy Benefit Managers and Health Maintenance Organizations
— Some states, including Tennessee, have chosen to use pharmacy benefit
managers (PBMs) to manage their prescription drug benefits. PBMs serve
as intermediaries between the state Medicaid program and pharmaceuti-
cal manufacturers and are able to negotiate significant discounts. They
often perform a variety of other services, including disease management.
Other states have pulled prescription drugs from their fee-for-service pro-
grams and rely on managed care organizations (MCOs) to manage their
More than 80 percent
of total Medicaid ex-
penditures are attribut-
able to the treatment of
chronic conditions.
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prescription drug benefit. Unlike states, MCOs are not able to collect
manufacturer rebates through the Medicaid Drug Rebate Program. Med-
icaid MCOs negotiate independently with drug manufacturers, either di-
rectly or through PBMs, in order to receive discounts and rebates.
Step Therapy/Fail First Policies — “Fail first” or “step therapy” policies
are similar in their operation to prior authorization requirements. Before
a physician is permitted to prescribe a newer, more expensive drug for a
patient, the physician must demonstrate that the alternative (and less
expensive) therapy has failed to prove effective for that patient. As they
do with prior authorization requirements, states may apply fail first poli-
cies to individual drugs or to classes of drugs.35 According to a survey
conducted by the Kaiser Commission on Medicaid and the Uninsured, at
least 11 states and the District of Columbia have fail first requirements for
one or more drugs.36
Strategies Directed at Drug Manufacturers and Pharmacies
Supplemental Rebates — In addition to the rebate required under fed-
eral Medicaid law, several states, including Maine and Florida, in yet an-
other effort to reduce their total spending on Medicaid prescription drugs,
have sought supplemental rebates from drug manufacturers. The way in
which these state rebate programs are designed differs from state to state,
but a key component generally involves the inclusion of the
manufacturer’s drugs in a state’s PDL in exchange for the manufacturer’s
provision of a supplemental rebate to the state. What may differ among
the state programs is the process by which beneficiaries may access those
drugs that are not included in the state’s PDL and the population that
benefits from the discounted drugs. For example, in the design of its pro-
gram, Maine Rx, the state of Maine has sought to extend discounted pre-
scription drugs and rebates beyond the Medicaid population to all unin-
sured Maine residents—regardless of income.37 In contrast, the Florida
program secures supplemental rebates only for prescription drugs pro-
vided to those individuals within the Medicaid population.38 As discussed
later in the paper, both the Maine and Florida programs are the subject of
pending litigation.
CMS issued an advisory on this issue in a letter to state Medicaid direc-
tors dated September 18, 2002. The intent of the letter was to clarify
issues related to supplemental drug rebate agreements and prior autho-
rization of Medicaid prescription drugs. The agency appeared to signal
that such agreements are acceptable and that states may use prior au-
thorization to encourage drug manufacturers to enter into these agree-
ments.39 Noting, however, that “the operation of a prior authorization
program used to negotiate drug discounts for the Medicaid popula-
tion is a significant component of a State plan,” the agency indicates
that both the agreement and the prior authorization program require
CMS approval.40 States that procure benefits, rebates, or discounts for
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non-Medicaid populations by linking them to a Medicaid prior autho-
rization program must also submit their program for CMS review but
are required to meet a more stringent standard. In such cases, “the
state should be prepared to demonstrate through appropriate evidence
that the prior authorization program will further the goals and objec-
tives of the Medicaid program.”41
Changes in Dispensing Fees and Reimbursement Formulas — Medic-
aid payments for prescription drugs include two components: (a) acqui-
sition costs and (b) dispensing fees. Both the acquisition costs, which cover
the cost of the drug itself, and the dispensing fees, which cover the cost of
filling the prescription, are paid to the pharmacy.42 State payments are
offset by rebates paid by drug manufacturers to the states in exchange
for the state's coverage of all of the manufacturer's drugs.
For acquisition costs, federal Medicaid regulations place limits on what
the federal government will match. For brand-name drugs or for ge-
neric drugs with fewer than three generic versions, the reimbursement
to the pharmacist is the lower of (a) the pharmacist’s usual and custom-
ary charge to the public and (b) the drug’s estimated acquisition cost
(EAC).43 Most states use a drug’s average wholesale price (AWP)44 to
calculate its EAC. Most states pay for drugs at a percentage discount
below a drug’s AWP, which ranged from AWP minus 4 percent in Wyo-
ming to AWP minus 15.1 percent (for pharmacies with more than five
stores) in Michigan in 2001.45 Other states use a markup from a drug’s
wholesale acquisition cost,46 and still others select the lower of the two
calculations. In their continued efforts to control costs, many states
are attempting to cut their payments to pharmacies by increasing the
percentage discount below AWP at which they pay for drugs. Others
are simply reducing dispensing fees. These initiatives are being met
with significant resistance from drug stores and pharmacists.
Purchasing Pools — Many states are looking to form purchasing pools
in order to increase their bargaining power with drug manufacturers
and secure the lowest possible prices for prescription drugs. Within
states, efforts are underway to pool purchases among state agencies
that provide coverage for different populations, including Medicaid
beneficiaries and state employees. In September 2001, a law went into
effect in Texas that established a multi-agency bulk-purchasing pro-
gram for prescription drugs. It combines prescription drug purchasing
for, among others, the departments of health and mental health, state
employees, teachers, and the state prison system. The state expects
savings of $13 million within the first two years.47
States are also looking beyond their borders to increase their leverage
with drug manufacturers. One initiative, the Northern New England Tri-
State Prescription Drug Purchasing Coalition, involves the states of Ver-
mont, Maine, and New Hampshire. In its first year, the coalition focused
on pooling the Medicaid populations of the three states, totaling 330,000
Many states are attempt-
ing to cut their payments
to pharmacies.
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individuals, and was to expand to other groups in subsequent years. By
increasing their purchasing power and efficiency, the three states are
expected to save 10 percent to 15 percent per year.48 The states have
selected a pharmacy benefit manager to manage the pool.
Another nine states have banded together to form the National Legisla-
tive Association on Prescription Drug Prices, a nonprofit organization
that would create PDLs and manage prescription drug benefits for state
employees and Medicaid beneficiaries. As a nonprofit, the organization
would negotiate discounts with manufacturers and pass the savings on
to the consumers in the participating states.
Many other collective purchasing arrangements are being explored by
states. Most of these efforts, including the above, are in the early stages
of formation or discussion; consequently, their potential for savings can-
not yet be evaluated.
Pharmacy Assessment Surcharges — Some states have elected to collect
a fee for all retail pharmaceutical sales, raising concern among retail phar-
macies that are also facing reduced dispensing fees and unpaid consumer
copayments. Efforts by pharmacies in Massachusetts to pass these fees on
to consumers have been met with a strict warning from state officials.
In regulations that went into effect on January 1, 2003, pharmacies in
Massachusetts are required to pay a surcharge of $1.30 for each non-
Medicaid, non-Medicare prescription dispensed. This assessment is ex-
pected to generate $36 million to offset increases in Medicaid drug costs.
In response to the new regulations, pharmacies within the state began to
impose the $1.30 surcharge on consumers, informing them that they were
required to do so. The regulations do not specify how pharmacies should
pay the surcharge. The state attorney general subsequently issued a letter
to the five major retail chains urging them to stop misleading the public
and warned them that some pharmacies were violating the state’s con-
sumer protection laws.49 In mid-February, the pharmacy chains agreed to
absorb the cost of the assessment and one chain even agreed to reimburse
individuals who had paid the $1.30 since the regulation was put into place.50
The charge is expected to drop to 65 cents in FY 2004, beginning on July 1.
Disclosure of Drug Company Marketing Activities — In an attempt to
limit the influence that drug manufacturers have over the prescribing pat-
terns of its state’s physicians, Vermont passed legislation in June 2002 that
requires pharmaceutical manufacturers to disclose to the state the “value,
nature and purpose” of their marketing activities within the state. Free
drug samples, clinical trials, and gifts with less than a $25.00 value are
exempt from the reporting requirements.51 The effects of this legislation
may not be known for some time, since the first reports from drug manu-
facturers are not due until January 1, 2004. Similar legislation has been
introduced in several other states, including Hawaii, Maryland, and Con-
necticut. These initiatives are not limited to Medicaid providers.
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STATE EXAMPLES
Maine
The state of Maine has been carefully watched over the past several years
because of a particularly controversial program that it has implemented
in its effort to control prescription drug spending under its Medicaid
program. Maine Rx, as it is known, would extend Medicaid discounts and
rebates to all uninsured residents of Maine. Though the discounts pro-
vided through Maine Rx benefit individuals ineligible for Medicaid, the
program directly affects Medicaid enrollees: a drug manufacturer's un-
willingness to participate in the program triggers a prior authorization
requirement for all the drugs it dispenses to Medicaid beneficiaries.52
This program has become mired in litigation and national political de-
bate, with other states awaiting the outcome of this case to learn if the
Maine law could become a reality within their own states. The Maine
program has yet to be implemented and remains on hold following a
challenge by the Pharmaceutical Research and Manufacturers Association
(PhRMA). PhRMA believes the Maine law violates federal Medicaid law
and amounts to an unconstitutional regulation of interstate commerce.
PhRMA also argues that the prior authorization component of the pro-
gram will cause harm to Medicaid beneficiaries by overly restricting ac-
cess to needed medications. PhRMA objects to the state’s extending “Med-
icaid-level discounts to non-Medicaid populations.”53
The Maine litigation reached the U.S. Supreme Court, where oral argu-
ment was heard on January 22. The Bush administration, business groups,
and conservative legal organizations have lined up in support of PhRMA,
while 28 states are backing Maine and approximately 12 are poised to
quickly pass similar laws if the Court sides with the state. As noted by
Maine’s former commissioner of the Department of Human Services,
Kevin Concannon, “as Maine goes, so goes the nation.”54 Whatever the
Supreme Court decision, it is expected to lead to an appeal to Congress to
act. The drug industry will be looking to prevent similar laws from pass-
ing in other states, and consumers and states will be looking for relief
from rising drug costs. Several of the Supreme Court justices appear to be
looking for guidance from the DHHS secretary.55 The Court is expected to
decide the case by this summer.
Michigan
Confronted with a 100 percent increase in Medicaid prescription drug
costs between FYs 1999 and 2002, Michigan in February 2002 implemented
the “Michigan Pharmaceutical Best Practices Initiative.”56 The program
applies to 1.5 million Michigan residents in Medicaid and other public
programs. The program established the Michigan Pharmaceutical Prod-
uct List (MPPL), a list of preferred drugs that could be prescribed with-
out prior authorization. The list includes: (a) those drugs deemed the
Michigan was con-
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best drugs in their class, or “reference drugs,” by the state’s pharmacy
and therapeutics committee; (b) those drugs for which the manufacturer
has agreed to offer a supplemental rebate; and (c) drugs priced lower
than the “reference drugs.” Drugs not included in the state’s PDL re-
quire prior authorization before dispensing. Limited exceptions were
made for certain beneficiaries already taking antipsychotic medications,
as well as for younger and older beneficiaries taking particular drugs.57
The state expects to save $850,000 per week under this program.58
Mental health patients, their advocates, and other consumer advocate
organizations have expressed serious concerns with the Michigan policy.
These center on the delicate medication regimen for mental health pa-
tients and the potential harm to the health and safety of all consumers.59
The Kaiser Commission on Medicaid and the Uninsured conducted a case
study that found that the MPPL was more restrictive with regard to cer-
tain categories of drugs, including mental health, cardiac, and diabetes
treatments, leading to decreased beneficiary access for these drugs. The
report also raised questions about the process by which the MPPL was
established and the way in which the program’s requirements were com-
municated to physicians, beneficiaries, pharmacies, and others.60
Michigan’s program faced a legal challenge from mental health advo-
cates and PhRMA, who raised questions about the process by which
Michigan’s policy was approved, namely, that it was never considered
by the full state legislature. The program was upheld by the Michigan
Court of Appeals in December 2002. In March 2003, a U.S. District Court
ruled that Michigan’s PDL, prior authorization, and supplemental rebate
policies were acceptable under federal law. PhRMA and two patient
groups have vowed to appeal this decision.
Florida
Spending for Medicaid prescription drugs increased by an average of 17
percent for each of the five years prior to 2001, eventually totaling $1.3
billion in FY 2000, or 17 percent of Florida’s total Medicaid spending.61
Following an evaluation of its prescription drug spending, the state con-
cluded that the increases it was experiencing were due primarily to doc-
tors’ switching patients to high-priced drugs and to price increases in
existing drugs. In response, in May 2001, legislation was passed, and a
Medicaid state plan amendment was approved by DHHS Secretary
Tommy Thompson, that allowed the state to negotiate directly with drug
manufacturers for supplemental rebates of 10 percent for prescription
drugs for Medicaid beneficiaries. Those drug manufacturers that provide
such rebates will have their drugs included in the state’s list of pre-
ferred drugs. If a drug is not on the state’s list, doctors must get verbal
authorization by calling a phone bank of pharmacists and pharmacy tech-
nicians before the prescription can be filled.
Florida’s spending for
Medicaid prescription
drugs increased by an
average of 17% for
each of the five years
before 2001.
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Drug manufacturers that prefer not to provide supplemental rebates have
the option of offering programs, such as disease management, that can
guarantee specified cost savings to the state. If a manufacturer’s program
fails to realize the stated savings, it will be required to make a payment to
the state to account for the difference. Two drug manufacturers, Pfizer
and Bristol-Myers Squibb, agreed to create programs for Florida Medic-
aid beneficiaries rather than provide supplemental rebates to the state.
Pfizer’s program involves disease management and health education that
targets four chronic conditions, with a guaranteed savings to the state of
$33 million. Bristol-Myers Squibb’s program focuses on improving the
health of chronically ill Hispanics and African-Americans and reducing
language and cultural barriers to care for Hispanic beneficiaries.62
PhRMA filed suit in federal court in August 2001 in an effort to stop
Florida’s program. It argued that the program violated federal Medicaid
law that requires states to cover all drugs of manufacturers that have en-
tered into rebate agreements with the federal government.63 The court
sided with Florida and allowed the program to move forward. This deci-
sion was upheld at the appellate level in September 2002, granting the
state yet another victory.
As with other programs that have the potential to limit access to certain
drugs, the Florida program has been carefully monitored by consumer
groups, who have identified safeguards that should be put in place to
ensure proper functioning of the program. These include timely determi-
nations of prior authorization and emergency provision of a short-term
supply of a drug when timely determinations are not possible, benefi-
ciary education, and staff qualified to make prior authorization decisions.
Florida doctors have also expressed concern that the state’s prior autho-
rization program could have a negative effect on patient care by interfer-
ing with doctors’ ability to choose the best drugs for their patients.64
CONCLUSION
Faced with extraordinary pressure to find ways to reduce their Medic-
aid expenditures, states continue to look in many directions for solu-
tions. A popular target of many of the states’ efforts has been prescrip-
tion drug spending. Efforts to control spending in this arena have been
met with significant debate and controversy, both of which are likely to
continue. Many issues will be debated and decided within the court
system and future state efforts are likely to be determined by these
judicial decisions. States will need to continue to find creative ways to
control spending while ensuring access to needed prescription drugs
for their low-income residents. The impact of state controls on each of
the various stakeholders—beneficiaries, providers, drug manufactur-
ers, and pharmacies—will need to be carefully assessed. From adminis-
trative requirements for prescribing physicians to lower reimbursement
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for pharmacies and increased cost sharing for beneficiaries, each cost-
saving measure will ask a particular stakeholder group to bear an in-
creased burden. The extent of that burden and potential unintended
consequences, including increased utilization of other health care ser-
vices such as hospitalization, will need to be monitored by states, par-
ticularly those states where multiple strategies are being implemented
simultaneously.
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